Safety and immunogenicity of a trivalent recombinant PcpA, PhtD, and PlyD1 pneumococcal protein vaccine in adults, toddlers, and infants: A phase I randomized controlled study.

CONCLUSIONS: The candidate trivalent PPrV was safe and immunogenic in adults, toddlers, and infants. Addition of aluminum adjuvant improved immunogenicity in infants without changing the safety profile. PMID: 26143615 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/26143615?dopt=Abstract

Source: Vaccine - July 1, 2015 Category: Allergy & Immunology Authors: Brooks WA, Chang LJ, Sheng X, Hopfer R, PPR02 Study Team Tags: Vaccine Source Type: research